NCT00985465CompletedPhase 3
Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Malian Children
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 218
- Locations
- 1
- Primary Endpoint
- Number of Subjects With Grade 3 Adverse Events (Solicited and Unsolicited)
Study Overview
Brief Summary
The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination in the second year of life to the Malian subjects previously enrolled in the primary vaccination study NCT00678301.
This protocol posting deals with objectives & outcome measures of the booster phase. The objectives & outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00678301).
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 15 Months to 21 Months (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR(s)) can and will comply with the requirements of the protocol.
- •A male or female, between and including 15-21 months of age at the time of visit
- •For the Pn-Pn group, subjects who completed the full vaccination course in study NCT
- •For the Zil-Pn group, subjects who were previously enrolled in the control group of study NCT
- •Written informed consent, signed or thumb printed, obtained from the parent(s)/LAR(s) of the subject. Where parent(s)/LAR(s) are illiterate, the consent form will be countersigned by a witness.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
Exclusion Criteria
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s)/product(s) within 30 days preceding the first dose of vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.
- •Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of study vaccine and ending 30 days after. Locally recommended vaccines for example Oral Polio Vaccine or influenza vaccine are always allowed, even if concomitantly administered with the study vaccines, but should be documented in the CRF.
- •Concurrently participating in another clinical study at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- •Administration of any pneumococcal vaccine since the end of study NCT
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, since the end of study NCT00678301, based on medical history and physical examination.
- •Major congenital defects or serious chronic illness.
- •History of any progressive neurological disorders or seizures.
- •Acute disease and/or fever at the time of enrolment.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •Administration of immunoglobulins and/or any blood products less than 3 months prior to visit 1 or planned use during the study.
- •Child in care.
Arms & Interventions
Pn-Pn group
Experimental
subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
Intervention: Pneumococcal vaccine GSK1024850A (Biological)
Zil-Pn group
Experimental
subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
Intervention: Pneumococcal vaccine GSK1024850A (Biological)
Outcomes
Primary Outcomes
Number of Subjects With Grade 3 Adverse Events (Solicited and Unsolicited)
Time Frame: Within 31 days (Day 0-Day 30) after booster vaccination
The incidence and nature of Grade 3 symptoms (solicited and unsolicited), reported during the 31-day (Days 0-30) post-vaccination are presented.
Secondary Outcomes
- Number of Subjects With Serious Adverse Events (SAEs)(From the first vaccination up to one month (31 days) after the last vaccination for each subject)
- Opsonophagocytic Activity Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F(Prior to (PRE) and one month after (POST) the booster immunization in the Synflorix Primed Group and prior to (PRE) the first dose and one month after (POST) the second dose of the catch-up vaccination in the Synflorix Unprimed Group)
- Concentrations of Antibodies Against Protein D (PD)(Prior to (PRE) and one month after (POST) the booster immunization in the Synflorix Primed Group and prior to (PRE) the first dose and one month after (POST) the second dose of the catch-up vaccination in the Synflorix Unprimed Group)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms(Within 4 days (Day 0-Day 3) after each vaccine dose)
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms(Within 4 days (Day 0-Day 3) after each vaccine dose)
- Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A(Prior to (PRE) and one month after (POST) the booster immunization in the Synflorix Primed Group and prior to (PRE) the first dose and one month after (POST) the second dose of the catch-up vaccination in the Synflorix Unprimed Group)
- Opsonophagocytic Activity Against Cross-reactive Pneumococcal Serotypes 6A and 19A(Prior to (PRE) and one month after (POST) the booster immunization in the Synflorix Primed Group and prior to (PRE) the first dose and one month after (POST) the second dose of the catch-up vaccination in the Synflorix Unprimed Group)
- Number of Subjects With Any Unsolicited Adverse Events (AEs)(Within 31 days (Day 0-Day 30) after each vaccine dose)
- Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F(Prior to (PRE) and one month after (POST) the booster immunization in the Synflorix Primed Group and prior to (PRE) the first dose and one month after (POST) the second dose of the catch-up vaccination in the Synflorix Unprimed Group)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in NigeriaInfections, StreptococcalNCT01153893GlaxoSmithKline105
Completed
Phase 3
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal InfectionInfections, StreptococcalStreptococcus Pneumoniae VaccinesNCT01746108GlaxoSmithKline52
Completed
Phase 3
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345InfluenzaNCT01702454GlaxoSmithKline470
Completed
Phase 3
Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 YearsHerpes ZosterNCT01777321GlaxoSmithKline60
Completed
Phase 1
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in ToddlersInfections, StreptococcalNCT01485406GlaxoSmithKline61